MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

94.35 0.56

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

93.66

Max

95.35

Galvenie mērījumi
By Trading Economics
Ienākumi	-125M 299M
Pārdošana	141M 1.5B
P/E Sektora vidējais	14.092 56.063
Peļņas marža	19.861
Darbinieki	2,844
EBITDA	-92M 415M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+16.51% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-3.4B 18B
Iepriekšējā atvēršanas cena	93.79
Iepriekšējā slēgšanas cena	94.35

Ziņu noskaņojums

By Acuity

42%

58%

142 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. apr. 22:56 UTC

Galvenie ziņu notikumi

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

2026. g. 1. apr. 20:50 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

2026. g. 1. apr. 23:55 UTC

Tirgus saruna

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

2026. g. 1. apr. 23:43 UTC

Tirgus saruna

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

2026. g. 1. apr. 23:23 UTC

Galvenie ziņu notikumi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

2026. g. 1. apr. 23:07 UTC

Peļņas

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

2026. g. 1. apr. 23:02 UTC

Galvenie ziņu notikumi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

2026. g. 1. apr. 22:39 UTC

Peļņas

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

2026. g. 1. apr. 22:08 UTC

Tirgus saruna

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

2026. g. 1. apr. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

2026. g. 1. apr. 21:31 UTC

Galvenie ziņu notikumi

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

2026. g. 1. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 1. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 1. apr. 20:38 UTC

Peļņas

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

2026. g. 1. apr. 20:31 UTC

Iegādes, apvienošanās, pārņemšana

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

2026. g. 1. apr. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

2026. g. 1. apr. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

2026. g. 1. apr. 20:13 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Extends Tender Offer To Acquire Arcellx >GILD

2026. g. 1. apr. 20:07 UTC

Tirgus saruna

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

2026. g. 1. apr. 20:07 UTC

Iegādes, apvienošanās, pārņemšana

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

16.51% augšup

Prognoze 12 mēnešiem

Vidējais 109.87 USD 16.51%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

142 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation